We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher (DHR) Beats on Q2 Earnings, Raises 2018 EPS View
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) is a global conglomerate that designs, manufactures and markets diverse lines of professional, medical, industrial, commercial and consumer products.
DHR’s tried and tested business model – the Danaher Business System (‘DBS’) – has proved to be the fundamental growth driver, fueling revenue, margins, cash flow and earnings improvement. Furthermore, DHR’s previously completed acquisitions have also been driving its top-line growth significantly. Furthermore, positive industry trends like new regulations from the Chinese Food and Drug Administration are expected to act as tailwinds.
Despite these positives, DHR has faced stunted organic revenue growth in its dental segment, mainly attributable to weakness in higher-margin traditional consumables business.
DHR consistently beat earnings in the trailing four quarters, with an average positive surprise of 4.09%.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Adjusted earnings per share for the second-quarter 2018 came in at $1.15 per share, which beat the Zacks Consensus Estimate of $1.09 per share.
Revenue: Revenues of $4,981 million topped the Zacks Consensus Estimate of $4,920 million.
Key Stats: Concurrent with the earnings release, DHR raised its full-year 2018 guidance. It now expects adjusted net earnings per share to lie in the range of $4.43-$4.50, compared to the earlier guided range of $4.38-$4.45. Overall, the company reported impressive, key metrics largely driven by its effective business model, the DBS, which focuses on three critical areas -- quality, delivery, and cost & innovation.
Stock Price: At the time of writing, the stock price of DHR was up nearly 2.25% ($2.22) in the pre-market trade on Nasdaq. Clearly the initial reaction to the release is optimistic. We view the company’s better-than-expected second-quarter 2018 result as the primary reason behind the positive sentiment.
As of Jul 18, 2018, DHR’s stock closed the trading session at $98.78 per share.
Check back our full write up on this DHR earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Danaher (DHR) Beats on Q2 Earnings, Raises 2018 EPS View
Danaher Corporation (DHR - Free Report) is a global conglomerate that designs, manufactures and markets diverse lines of professional, medical, industrial, commercial and consumer products.
DHR’s tried and tested business model – the Danaher Business System (‘DBS’) – has proved to be the fundamental growth driver, fueling revenue, margins, cash flow and earnings improvement. Furthermore, DHR’s previously completed acquisitions have also been driving its top-line growth significantly. Furthermore, positive industry trends like new regulations from the Chinese Food and Drug Administration are expected to act as tailwinds.
Despite these positives, DHR has faced stunted organic revenue growth in its dental segment, mainly attributable to weakness in higher-margin traditional consumables business.
DHR consistently beat earnings in the trailing four quarters, with an average positive surprise of 4.09%.
Currently, DHR has a Zacks Rank #3 (Hold) but that could change following its second-quarter 2018 earnings report which has just released. You can see the complete list of today’s Zacks #1(Strong Buy) Rank stocks here.
We have highlighted some of the key details from the just-released announcement below:
Earnings: Adjusted earnings per share for the second-quarter 2018 came in at $1.15 per share, which beat the Zacks Consensus Estimate of $1.09 per share.
Revenue: Revenues of $4,981 million topped the Zacks Consensus Estimate of $4,920 million.
Key Stats: Concurrent with the earnings release, DHR raised its full-year 2018 guidance. It now expects adjusted net earnings per share to lie in the range of $4.43-$4.50, compared to the earlier guided range of $4.38-$4.45. Overall, the company reported impressive, key metrics largely driven by its effective business model, the DBS, which focuses on three critical areas -- quality, delivery, and cost & innovation.
Stock Price: At the time of writing, the stock price of DHR was up nearly 2.25% ($2.22) in the pre-market trade on Nasdaq. Clearly the initial reaction to the release is optimistic. We view the company’s better-than-expected second-quarter 2018 result as the primary reason behind the positive sentiment.
As of Jul 18, 2018, DHR’s stock closed the trading session at $98.78 per share.
Danaher Corporation Price
Danaher Corporation Price | Danaher Corporation Quote
Check back our full write up on this DHR earnings report later!
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>